GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Virax Biolabs Group VRAX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.71

-10.35%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$12,423

FY2020FY2026

Net income

−$5.0m

FY2020FY2026

Free cash flow

−$4.9m

FY2020FY2026

Shareholders' equity

$7.6m

FY2020FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Revenue$12,423$6,331$156,419$8,561—$123,820$99,876
Research and development$3.7m$1.8m$1.6m$397,109$433,743$120,221$87,000
Operating income−$6.4m−$6.2m−$6.5m−$5.7m−$1.7m−$644,540−$651,244
Net income−$5.0m−$6.1m−$6.7m−$5.5m−$1.7m−$650,984−$801,131
Diluted earnings per share-12.64-31.82-54.26-76.87-1.10-0.06-0.07

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Total assets$8.3m$6.4m$5.5m$9.8m$48,706$94,118$22,609
Cash and short-term investments$6.5m$4.2m$3.6m$9.4m$21,756$17,621$22,609
Total liabilities$989,831$964,750$345,194$908,401$1.2m$871,435$1.2m
Debt$414,387$377,004$224,300$146,250$3,758$179,480$759,370
Shareholders' equity$7.6m$5.7m$5.4m$9.1m−$974,578−$596,185−$1.1m
Shares outstanding0m0m0m0m2m11m11m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations−$4.6m−$4.6m−$6.2m−$4.2m−$809,069−$590,186−$744,613
Capital spending−$255,830−$603,890−$1.2m−$178,403———
Free cash flow−$4.9m−$5.2m−$7.4m−$4.4m−$809,069−$590,186−$744,613

Latest quarters

By quarter end

Jun 2026Sept 2025Jun 2025Mar 2025Sept 2024Jun 2024Mar 2024Sept 2023
Revenue$12,423$1,608$1,378$1,400$4,953$79,919$79,900$76,500
Operating income−$6.4m−$2.6m−$3.3m−$3.3m−$2.9m−$3.8m−$3.4m−$2.7m
Net income−$5.0m−$2.3m−$3.3m−$3.3m−$2.8m−$3.8m−$3.8m−$2.9m
Diluted earnings per share-12.64-12.28-17.35-0.76-22.21-30.81-1.71-40.98
Cash from operations−$4.0m−$2.0m−$2.0m−$2.0m−$1.0m−$2.0m−$2.0m−$3.0m
Total assets$8.3m$5.7m$6.4m$6.4m$9.4m$5.5m$5.5m$7.0m
Cash and short-term investments$6.5m$3.3m$4.2m—$7.4m$3.6m—$5.1m
Debt$109,579$261,950$85,461—$271,104$47,955—$49,679
Shareholders' equity$7.6m$5.3m$5.7m$5.7m$8.6m$5.4m$5.4m$6.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue13.2%-36.9%—
Operating income3.7%58.3%—
Net income-2.7%50.5%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-66986.4%-13493.3%——
Net margin-59107.4%-12668.3%——

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022
Price to earnings-0.1-0.2-0.7-0.3-106.5
Price to sales38.4166.928.6194.2—

Share price return

Finished calendar years

2025202420232022
Return-84%65%-77%-97%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 25-to-1 reverse split · 26 Jun 2026
  • 10-to-1 reverse split · 18 Dec 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.